Dizal Pharmaceuticals

This study tests a new drug called golidocitinib against standard treatments for adults with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. About 218 participants will be randomly assigned to receive either golidociti…

This study tests two experimental drugs (DZD9008 and AZD4205) together in people with advanced non-small cell lung cancer that has EGFR mutations and has stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About 90 adult…

This study tests an experimental drug called DZD8586 in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed at least one standard treatment and have low platelet counts. T…

This study tests a new combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose, and the second part compares the combo to standard chemotherapy. About 165 adults with this rare blood cancer will take part.

This study tests a new drug, DZD8586, in about 155 adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned, stopped responding to prior treatment, or caused unbearable side effects. The goal is to see how well the drug shrinks tumors and what side eff…

This early-stage study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene changes. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. About 140 adults whose c…

This study tests a new drug, DZD8586, combined with other treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. About 150 adults with untreated or relapsed/refractory DLBCL will participate. The goal is to see if the combination shrinks tumors and to …

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This early-stage study tests a new drug, DZD6008, in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety and find the right dose. About 190 adults will take part, and researchers will also watch for any …